Lukas, Martin <br/><br/>
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.  [electronic resource] 

 -  Journal of Crohn's & colitis  Jul 2020 
 - 915-919 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1876-4479 
<br/><br/><label>Standard No.: </label>10.1093/ecco-jcc/jjaa001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--blood<br/>Adult<br/>Antibodies--blood<br/>Biosimilar Pharmaceuticals--blood<br/>C-Reactive Protein--metabolism<br/>Colitis, Ulcerative--blood<br/>Crohn Disease--blood<br/>Drug Substitution<br/>Feces--chemistry<br/>Female<br/>Gastrointestinal Agents--blood<br/>Humans<br/>Leukocyte L1 Antigen Complex--analysis<br/>Male<br/>Middle Aged<br/>Retrospective Studies<br/>Severity of Illness Index<br/>Tertiary Care Centers<br/>Treatment Outcome